Immunomodulating treatments of body cavities
Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
1. A method of treatment for a cancer of an internal body cavity in a human subject, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of:
(a) a TLR agonist comprising an imidazoquinolin amine provided at a concentration of 0.005% (w/v) to 10% (w/v), and
(b) an immune checkpoint antagonist comprising an anti-CTLA-4 antibody,
wherein at least one of the TLR agonist and the immune checkpoint antagonist are provided in a thermoreversible hydrogel composition comprising a poloxamer, and
wherein at least (a) is administered locally into the internal body cavity,
thereby treating the cancer of the body cavity.
2. The method of claim 1 wherein the immune checkpoint antagonist is an anti-CTLA4 antibody selected from the group consisting of: Ipilimumab (Yervoy), Tremelimumab (CP-675,206), AGEN-1884, AGEN-2041 (AGEN-1181), ADU-1604, AK 104, BCD-145, BMS-986249, CBT-509, ATOR 1144, and ATOR-1015.
3. The method of claim 1 , wherein the poloxamer has an average molecular weight of 8500-16000DA, inclusive.
4. The method of claim 1 , wherein the Poloxamer comprises Poloxamer 407, Poloxamer 188, Poloxamer 124, Poloxamer 237, or Poloxamer 338 or combination thereof.
5. The method of claim 1 , wherein the cancer is selected from the group consisting of bladder cancer, urinary tract cancer, upper urinary tract cancer, renal cancer, gastrointestinal cancer, colon cancer, rectal cancer, and female reproductive system cancer.
6. The method of claim 1 , wherein the thermoreversible hydrogel composition further comprises a mucoadhesive polymer.
7. The method of claim 1 , wherein the thermoreversible hydrogel composition comprises 15% (w/w)-40% (w/w) poloxamer 407.
8. The method of claim 1 wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimuab provided at a concentration 1 (mg/Kg B·W) to 50 (mg/Kg B·W).
9. The method of claim 1 , wherein the TLR agonist is administered intravesically.
10. The method of claim 1 , wherein the TLR agonist and the immune checkpoint antagonist modulator are provided in the thermoreversible hydrogel intravesically into the internal body cavity.
11. The method of claim 1 , wherein the TLR agonist and immune checkpoint antagonist modulators are administered simultaneously, repetitively, in sequence or in any combination thereof.
12. A method for inhibiting re-growth of a cancer of an internal body cavity in a human subject, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of:
a TLR agonist comprising an imidazoquinolin amine provided at a concentration of 0.005% (w/v) to 10% (w/v), and
an immune checkpoint antagonist comprising an anti-CTLA-4 antibody,
wherein at least one of the TLR agonist and the immune checkpoint antagonist are provided in a thermoreversible hydrogel composition comprising a poloxamer,
and wherein the TLR agonist and immune checkpoint antagonist are administered to the subject subsequent to a treatment for the cancer which removed or decreased the amount of the cancer in the subject, thereby inhibiting the regrowth cancer of the body cavity.
13. The method of claim 1 , further comprising a wash of the internal body cavity between (a) and (b).
14. The method of claim 1 , wherein the imidazoquinoline amine is imiquimod.
15. The method of claim 12 , wherein the imidazoquinolin amine is imiquimod.